(Q37900615)

English

Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials

scientific article published on August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

0 references

1 reference

Europe PubMed Central

Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

0 references

systematic review

1 reference

based on heuristic

inferred from title

Scott B. Patten

4

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

author name string

Tamara Pringsheim

1

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Darren Lam

2

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Heidi Ching

3

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

651-668

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

https://scigraph.springernature.com/pub.10.2165/11592020-000000000-00000

0 references

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000.

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Extrapyramidal side-effects of antipsychotics in a randomised trial

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Effects of development on olanzapine-associated adverse events

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Risperidone in children with autism and serious behavioral problems

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

A double-blind pilot study of risperidone in the treatment of conduct disorder

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Olanzapine versus placebo in the treatment of adolescents with bipolar mania

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Childhood predictors of the metabolic syndrome in adulthood. The Cardiovascular Risk in Young Finns Study.

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Risk factors identified in childhood and decreased carotid artery elasticity in adulthood: the Cardiovascular Risk in Young Finns Study

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

1 reference

https://api.crossref.org/works/10.2165%2F11592020-000000000-00000

21 January 2018

A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current methods of the US Preventive Services Task Force: a review of the process

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone in children with autism: randomized, placebo-controlled, double-blind study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Childhood Overweight Status Predicts Diabetes at Age 21 Years: A Follow-up Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21751826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11592020-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37900615&oldid=2106158662"